TD Cowen on Benitec BioPharma (BNTC): 'Updated Interim Ph1/2 '301 OPMD Dysphagia Data Impresses'
Tweet Send to a Friend
TD Cowen analyst Ritu Baral reiterated a Buy rating on Benitec BioPharma (NASDAQ: BNTC).The analyst commented: "Updated Interim Ph1/2 '301 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
